42 results on '"Cedena, Teresa"'
Search Results
2. OA-12 Predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible multiple myeloma (MM) patients
3. P-367 High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
4. OA-02 α-NKG2A blockade overcomes multiple myeloma resistance to BCMA and NKG2D CAR-NKAE cells
5. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
6. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis
7. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts
8. Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology
9. P-226: Clinical outcomes of Multiple Myeloma patients after anti-CD38 monoclonal antibodies failure
10. P-007: Exploring a safety switch in NKG2D and BCMA CAR NK-92MI immunotherapy
11. Paroxysmal nocturnal hemoglobinuria: a single Spanish centerʼs experience over the last 40 yr
12. Microfluidic-assisted engineering of multi-layered microcapsules for 3D stem cell culture
13. Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
14. Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients
15. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
16. Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
17. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
18. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
19. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
20. Ocena minimalnej choroby resztkowej w szpiczaku plazmocytowym
21. Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients
22. Minimal residual disease testing for multiple myeloma.
23. The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients
24. Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials
25. Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
26. Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma
27. Interlaboratory Variation in CD34+ Cell Quantification in Low Risk Myelodysplastic Syndromes
28. Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study
29. What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity
30. Minimal residual disease testing for multiple myeloma.
31. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts
32. Paroxysmal nocturnal hemoglobinuria: a single S panish center's experience over the last 40 yr
33. Analysis Of Transfusion Dependence Development and Disease Evolution In Patients With MDS and Del(5q) and Without Transfusion Needs At Diagnosis
34. Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients
35. The Challenge Of Quantifying CD34+ Myeloid Cells In Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts. Reproducibility Among 6 Flow Cytometry Observers
36. Inter-Observer Discordance With The Diagnosis Of Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts: Unilineage Vs Multilineage Dysplasia and Reproducibility Of The Threshold Of 2% Blasts
37. Aplicability Of The Predictive Model Of Response To Erythropoetic Stimulating Agents (ESA) From Myelodysplastic Syndromes (MDS) and Analysis Of Response and Overall Survival (OS) In a Series Of 99 Patients (Pts) With Chronic Myelomonocytic Leukemia (CMML) From The Spanish Registry Of MDS and The Düsseldorf-MDS Registry, Germany
38. Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn 7)? Results of a Retrospective Study From the GFM and GESMD Registries
39. Exploring a safety switch in NKG2D and BCMA CAR NK-92MI immunotherapy
40. CLINICAL VALIDATION OF SIMPLIFIED METHOD OF MASSIVE SEQUENCING FOR QUANTIFICATION OF RESIDUAL DISEASE IN MULTIPLE MYELOMA
41. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study.
42. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.